• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Search Orphan Drug Designations and Approvals

  • Print
  • Share
  • E-mail
-
Generic Name: deferiprone
Trade Name: Ferriprox
Date Designated: 12/12/2001
Orphan Designation: Treatment of iron overload in patients with hematologic disorders requiring chronic transfusion therapy
Orphan Designation Status: Designated/Approved
Chiesi USA, Inc.
175 Regency Woods Place
Suite 600
Cary, North Carolina 27518
United States

The sponsor address listed is the last reported by the sponsor to OOPD.

Marketing approved:

1 Generic Name: deferiprone
Trade Name: Ferriprox
Marketing Approval Date: 10/14/2011
Approved Labeled Indication: Treatment of patients with transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate
Exclusivity End Date: 10/14/2018 
Exclusivity Protected Indication* :  
2 Generic Name: deferiprone
Trade Name: Ferriprox
Marketing Approval Date: 05/19/2020
Approved Labeled Indication: Ferriprox (deferiprone) is indicated for the treatment of patients with transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate.
Exclusivity End Date: TBD  
3 Generic Name: deferiprone
Trade Name: Ferriprox
Marketing Approval Date: 04/30/2021
Approved Labeled Indication: treatment of transfusional iron overload in adult and pediatric patients 8 years of age and older with thalassemia syndromes; and treatment of transfusional iron overload in adult and pediatric patients 8 years of age and older with sickle cell disease or other anemias
Exclusivity End Date: TBD  
4 Generic Name: deferiprone
Trade Name: Ferriprox
Marketing Approval Date: 04/30/2021
Approved Labeled Indication: treatment of transfusional iron overload in adult and pediatric patients 3 years of age and older with thalassemia syndromes; and treatment of transfusional iron overload in adult and pediatric patients 3 years of age and older with sickle cell disease or other anemias
Exclusivity End Date: TBD  

*Exclusivity Protected Indications are shown for approvals from Jan. 1, 2013, to the present.
-
-